Muzykantov V R, Gavriluk V D, Reinecke A, Atochina E N, Kuo A, Barnathan E S, Fisher A B
Institute for Environmental Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.
Anal Biochem. 1995 Apr 10;226(2):279-87. doi: 10.1006/abio.1995.1226.
The effect of modification with biotin N-hydroxysuccinimide ester of mouse monoclonal antibody to angiotensin-converting enzyme, anti-ACE Mab 9B9, on its targeting to endothelial cells has been studied in vitro and in vivo. By in vitro assay, Mab 9B9 biotinylated at a biotin/IgG molar ratio in reaction mixture (B/IgG ratio) of 0.7-2.2 bound streptavidin monovalently and retained antigen-binding capacity. Mab 9B9 biotinylated at a B/IgG ratio of 20 and higher bound streptavidin polyvalently. Extensive biotinylation (B/IgG ratio of 60 and higher) led to dramatic reduction of Mab 9B9 Ag-binding capacity and to reduction of Mab 9B9 recognition by goat polyclonal antibody to mouse IgG. Radiolabeled Mab 9B9 biotinylated at a B/IgG ratio of 6 (b6-Mab 9B9) bound effectively to cultured vascular endothelium, with affinity characteristics similar to nonbiotinylated Mab 9B9. Endothelial cells internalized both Mab 9B9 and b6-Mab 9B9 to the same extent (60% internalization at 3 h incubation at 37 degrees C). Degradation of cell surface-associated Mab 9B9 or b6-Mab 9B9 was very low (< 1% as measured by TCA solubility of radiolabel). In contrast, degradation of internalized b6-Mab 9B9 was more profound than that of Mab 9B9 (20 +/- 3% vs 6 +/- 1%, P < 0.01). After injection in rats, radiolabeled b6-Mab 9B9 had a biodistribution pattern similar to that of radiolabeled Mab 9B9. Both preparations effectively accumulated in the lung (15-20% of injected dose/g of tissue vs 2% of injected dose/g of blood).(ABSTRACT TRUNCATED AT 250 WORDS)
已在体外和体内研究了用生物素N-羟基琥珀酰亚胺酯修饰的小鼠抗血管紧张素转换酶单克隆抗体(抗ACE Mab 9B9)对其靶向内皮细胞的影响。通过体外测定,在反应混合物中生物素/IgG摩尔比(B/IgG比)为0.7 - 2.2时生物素化的Mab 9B9以单价结合链霉亲和素并保留抗原结合能力。在B/IgG比为20及更高时生物素化的Mab 9B9以多价结合链霉亲和素。广泛生物素化(B/IgG比为60及更高)导致Mab 9B9的Ag结合能力显著降低,并导致山羊抗小鼠IgG多克隆抗体对Mab 9B9的识别减少。在B/IgG比为6时生物素化的放射性标记Mab 9B9(b6-Mab 9B9)有效地结合到培养的血管内皮,其亲和特性与未生物素化的Mab 9B9相似。内皮细胞以相同程度内化Mab 9B9和b6-Mab 9B9(在37℃孵育3小时时内化率为60%)。细胞表面相关的Mab 9B9或b6-Mab 9B9的降解非常低(通过放射性标记的TCA溶解度测量<1%)。相反,内化的b6-Mab 9B9的降解比Mab 9B9更显著(20±3%对6±1%,P<0.01)。在大鼠体内注射后,放射性标记的b6-Mab 并保留抗原结合能力。在B/IgG比为20及更高时生物素化的Mab 9B9以多价结合链霉亲和素。广泛生物素化(B/IgG比为60及更高)导致Mab 9B9的Ag结合能力显著降低,并导致山羊抗小鼠IgG多克隆抗体对Mab 9B9的识别减少。在B/IgG比为6时生物素化的放射性标记Mab 9B9(b6-Mab 9B9)有效地结合到培养的血管内皮,其亲和特性与未生物素化的Mab 9B9相似。内皮细胞以相同程度内化Mab 9B9和b6-Mab 9B9(在37℃孵育3小时时内化率为60%)。细胞表面相关的Mab 9B9或b6-Mab 9B9的降解非常低(通过放射性标记的TCA溶解度测量<1%)。相反,内化的b6-Mab 9B9的降解比Mab 9B9更显著(20±3%对6±1%,P<0.01)。在大鼠体内注射后,放射性标记的b6-Mab 9B9具有与放射性标记的Mab 9B9相似的生物分布模式。两种制剂都有效地在肺中蓄积(每克组织注射剂量的15 - 20%对每克血液注射剂量的2%)。(摘要截短于250字) 9B9具有与放射性标记的Mab 9B9相似的生物分布模式。两种制剂都有效地在肺中蓄积(每克组织注射剂量的15 - 20%对每克血液注射剂量的2%)。(摘要截短于250字)